Chronic renal failure-induced multiple-organ injury in rats is alleviated by the selective CysLT1 receptor antagonist montelukast
Introduction
Chronic inflammation is a highly prevalent co-morbid condition that predicts poor clinical outcome in end-stage renal disease (ESRD) patients [1], [2], [3], enhancing mainly cardiovascular risk and mortality [4]. Evidence for oxidative stress in chronic renal failure (CRF) was based on the elevation of toxic lipid peroxidation products, which cause destruction and damage to cell membranes [5], [6], [7], [8]. Several earlier studies have revealed that these toxic products cause an inflammatory burden in CRF through the generation of an imbalance between increased production of reactive oxygen species (ROS) and limited or decreased antioxidant capacity [9].
A wide array of inflammatory biomarkers, such as C-reactive protein, interleukin (IL)-6 and white blood cell count, has been proven to be robust predictors of poor outcome in the ESRD patients [9], [10]. It is well documented that the inflammatory response in CRF is characterized by activation of neutrophils and collective action of chemotactic mediators [11]. The cellular sources of inflammatory cytokines enhanced in ESRD patients are mainly neutrophils and monocytes. Once neutrophils migrate into the tissue, they release reactive oxygen species, proteases, elastase, myeloperoxidase (MPO), cytokines and various other mediators [12]. Along with the various pro-inflammatory chemokines, cysteinyl leukotrienes (CysLTs), the 5-lipoxygenase metabolites of arachidonic acid, are also proven to be potent inflammatory mediators that cause tissue injury.
Antileukotriene drugs, i.e. leukotriene receptor antagonists and synthesis inhibitors, are a new class of anti-inflammatory drugs that have shown efficacy in the treatment of several inflammatory models. A selective reversible CysLT1 receptor antagonist, montelukast (MK-0476), was used in the treatment of asthma and is reported to reduce eosinophilic inflammation in the airways [13], [14], while CysLT1 receptor antagonists or biosynthesis inhibitors have been reported to ameliorate ethanol-induced gastric mucosal damage [15], [16] and experimental colitis [17]. Recently, we have shown that the CysLT1 receptor antagonist, montelukast, ameliorates burn- and sepsis-induced multiple organ damage [18], [19]. Furthermore, we have reported that montelukast improved microscopic damage and renal function and protected against renal ischemia/reperfusion injury in rats [20]. These data suggest that limiting the inflammatory cascade by blocking the CysLT1 receptors may also limit the oxidative damage induced by CRF. Therefore, using a rat model of chronic renal failure, the present study was designed to elucidate the putative protective effect of montelukast on renal functions and oxidant/antioxidant status of the kidney and the affected organs, lung, heart and brain.
Section snippets
Animals
Male Wistar albino rats (200–250 g) were housed in a room at a constant temperature of 22 ± 2 °C with a 12 h light–dark cycle, and had free access to standard pellet chow and water. All experimental protocols were approved by the Marmara University School of Medicine Animal Care and Use Committee.
Surgery and experimental protocol
The animals (n = 32) were randomly assigned to either the CRF group or the sham-operated control group. Under ketamine anesthesia (100 mg/kg ketamine and 0.75 mg/kg chlorpromazine; i.p.) and aseptic conditions,
Results
The BUN and creatinine levels in the saline-treated CRF group were found to be significantly higher than those in the sham-operated control rats treated with either montelukast or saline (p < 0.001; Table 1). Montelukast treatment in the CRF group reversed the serum creatinine level back to control levels, and significantly reduced the BUN level (p < 0.001). Serum LDH activity showed a significant increase in the saline-treated CRF group, indicating a generalized tissue damage (p < 0.01), while
Discussion
As observed by increased lipid peroxidation, collagen content and myeloperoxidase activity and decreased GSH level, the present results demonstrate that CRF in rats yields to oxidative injury in the renal tissue, as well as in the lung, heart and brain tissues. These observed tissue damages were accompanied by elevated serum levels of pro-inflammatory mediators (LTB4, TNF-α, IL-1β and IL-6), while histological analyses verified the severity of CRF-induced systemic inflammatory response in all
References (52)
Oxidative stress in uremia: nature, mechanisms, and potential consequences
Semin Nephrol
(2004)- et al.
C-reactive protein as an outcome predictor for maintenance hemodialysis patients
Kidney Int
(1998) - et al.
Inflammation enhances cardiovascular risk and mortality in hemodialysis patients
Kidney Int
(1999) - et al.
Superoxide anion generation, erythrocytes superoxide dismutase activity, and lipid peroxidation during hemoperfusion and hemodialysis in chronic uremic patients
Free Radic Biol Med
(1989) - et al.
Role of increased oxygen free radical activity in the pathogenesis of uremic hypertension
Kidney Int
(1998) - et al.
Inflammatory reaction and infection in severe burns
Pathol Biol
(2002) - et al.
Effects of leukotrienes on susceptibility of the rat stomach to damage and investigation of the mechanism of action
Gastroenterology
(1990) - et al.
Leukotriene receptor blocker montelukast protects against burn-induced oxidative injury of the skin and remote organs
Burns
(2005) - et al.
Amelioration of sepsis-induced hepatic and ileal injury in rats by the leukotriene receptor blocker montelukast
Prostoglandins Leukot Essent Fatty Acids
(2005) - et al.
Oxidative stress and dysregulation of superoxide dismutase and NADPH oxidase in renal insufficiency
Kidney Int
(2003)